Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - (Placebo-Controlled, Double Blind and Randomized Phase III Study of Intravaginal Prasterone)

Trial Profile

Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - (Placebo-Controlled, Double Blind and Randomized Phase III Study of Intravaginal Prasterone)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Dec 2017

At a glance

  • Drugs Prasterone (Primary)
  • Indications Decreased libido
  • Focus Therapeutic Use
  • Sponsors Endoceutics
  • Most Recent Events

    • 31 Oct 2017 Status changed from not yet recruiting to recruiting.
    • 02 Oct 2017 Planned initiation date changed from 1 Sep 2017 to 1 Oct 2017.
    • 22 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top